ABUS — Arbutus Biopharma Balance Sheet
0.000.00%
- $629.97m
- $507.35m
- $6.17m
Annual balance sheet for Arbutus Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 123 | 155 | 147 | 126 | 123 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.31 | 0.899 | 1.35 | 1.78 | 2.41 |
Prepaid Expenses | |||||
Total Current Assets | 128 | 161 | 151 | 132 | 127 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 9.33 | 8.07 | 6.81 | 6.09 | 4.36 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 137 | 204 | 195 | 144 | 132 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9.54 | 11.2 | 32.9 | 22.5 | 15.6 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 35.1 | 35 | 58.6 | 38.4 | 34.3 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 102 | 169 | 137 | 106 | 97.4 |
Total Liabilities & Shareholders' Equity | 137 | 204 | 195 | 144 | 132 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |